Estrogen receptors (ERs) have pivotal roles in the development and progression of triple-negative breast cancer (TNBC). Interactions among cancer cells and tumor microenvironment are orchestrated by the extracellular matrix that is rapidly emerging as prominent contributor of fundamental processes of breast cancer progression. Early studies have correlated ER beta expression in tumor sites with a more aggressive clinical outcome, however ER beta exact role in the progression of TNBC remains to be elucidated. Herein, we introduce the functional role of ER beta suppression following isolation of monoclonal cell populations of MDA-MB-231 breast cancer cells transfected with shRNA against human ESR2 that permanently resulted in 90% reduction of ER beta mRNA and protein levels. Further, we demonstrate that clone selection results in strongly reduced levels of the aggressive functional properties of MDA-MB-231 cells, by transforming their morphological characteristics, eliminating the mesenchymal-like traits of triple-negative breast cancer cells. Monoclonal populations of shER beta MDA-MB-231 cells undergo universal matrix reorganization and pass on a mesenchymal-to-epithelial transition state. These striking changes are encompassed by the total prevention of tumorigenesis in vivo following ER beta maximum suppression and isolation of monoclonal cell populations in TNBC cells. We propose that these novel findings highlight the promising role of ER beta targeting in future pharmaceutical approaches for managing the metastatic dynamics of TNBC breast cancer.

ESR2 Drives Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer and Tumorigenesis In Vivo / Piperigkou, Zoi; Koutsandreas, Anastasios; Franchi, Marco; Zolota, Vasiliki; Kletsas, Dimitrios; Passi, Alberto; Karamanos, Nikos K. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - ELETTRONICO. - 12:(2022), pp. 917633.1-917633.14. [10.3389/fonc.2022.917633]

ESR2 Drives Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer and Tumorigenesis In Vivo

Franchi, Marco;
2022

Abstract

Estrogen receptors (ERs) have pivotal roles in the development and progression of triple-negative breast cancer (TNBC). Interactions among cancer cells and tumor microenvironment are orchestrated by the extracellular matrix that is rapidly emerging as prominent contributor of fundamental processes of breast cancer progression. Early studies have correlated ER beta expression in tumor sites with a more aggressive clinical outcome, however ER beta exact role in the progression of TNBC remains to be elucidated. Herein, we introduce the functional role of ER beta suppression following isolation of monoclonal cell populations of MDA-MB-231 breast cancer cells transfected with shRNA against human ESR2 that permanently resulted in 90% reduction of ER beta mRNA and protein levels. Further, we demonstrate that clone selection results in strongly reduced levels of the aggressive functional properties of MDA-MB-231 cells, by transforming their morphological characteristics, eliminating the mesenchymal-like traits of triple-negative breast cancer cells. Monoclonal populations of shER beta MDA-MB-231 cells undergo universal matrix reorganization and pass on a mesenchymal-to-epithelial transition state. These striking changes are encompassed by the total prevention of tumorigenesis in vivo following ER beta maximum suppression and isolation of monoclonal cell populations in TNBC cells. We propose that these novel findings highlight the promising role of ER beta targeting in future pharmaceutical approaches for managing the metastatic dynamics of TNBC breast cancer.
2022
ESR2 Drives Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer and Tumorigenesis In Vivo / Piperigkou, Zoi; Koutsandreas, Anastasios; Franchi, Marco; Zolota, Vasiliki; Kletsas, Dimitrios; Passi, Alberto; Karamanos, Nikos K. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - ELETTRONICO. - 12:(2022), pp. 917633.1-917633.14. [10.3389/fonc.2022.917633]
Piperigkou, Zoi; Koutsandreas, Anastasios; Franchi, Marco; Zolota, Vasiliki; Kletsas, Dimitrios; Passi, Alberto; Karamanos, Nikos K
File in questo prodotto:
File Dimensione Formato  
Zoi et al. Frontiers in Oncology OK.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 8.79 MB
Formato Adobe PDF
8.79 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/907529
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact